Q3 2016 13F Holders as of 30 Sep 2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
123,650,000
-
Number of holders
-
161
-
Total 13F shares, excl. options
-
106,009,210
-
Shares change
-
+1,018,812
-
Total reported value, excl. options
-
$1,279,976,335
-
Value change
-
+$17,256,778
-
Put/Call ratio
-
39%
-
Number of buys
-
71
-
Number of sells
-
-73
-
Price
-
$12.08
Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q3 2016
199 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q3 2016.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 161 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 106,009,210 shares
of 123,650,000 outstanding shares and own 86% of the company stock.
Largest 10 shareholders include Third Security, LLC (19,305,403 shares), IRIDIAN ASSET MANAGEMENT LLC/CT (9,290,024 shares), VANGUARD GROUP INC (8,199,259 shares), FMR LLC (7,806,475 shares), First Eagle Investment Management, LLC (7,395,500 shares), BB BIOTECH AG (7,379,832 shares), BlackRock Fund Advisors (4,518,198 shares), STATE STREET CORP (3,261,211 shares), BlackRock Institutional Trust Company, N.A. (3,005,011 shares), and JPMORGAN CHASE & CO (2,980,634 shares).
This table shows the top 161 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.